Moderna on April 28 said it has asked the U.S. Food and Drug Administration (FDA) to grant emergency use authorization (EUA) to the company for its COVID-19 vaccine for children as young as 6 months.
The EUA submission is for two 25-microgram doses of the shot, mRNA-1273, in children 6 months old to 5 years old.
“We are proud to share that we have initiated our EUA submission for authorization for our COVID-19 vaccine for young children,” Stéphane Bancel, Chief CEO of the Massachusetts-based biotechnology firm, said in a statement. “We believe mRNA-1273 will be able to safely protect these children against SARS-CoV-2, which is so important in our continued fight against COVID-19 and will be especially welcomed by parents and caregivers.”
…